人類乳突病毒(HPV)檢驗的全球市場，市場規模和佔有率的分析 - 成長趨勢與預測(2025年～2033年)

人類乳突病毒 (HPV) 檢測市場趨勢及總結

2024 年全球人類乳突病毒 (HPV) 檢測市場規模為 15.2 億美元，預計到 2033 年將達到 36.2 億美元，2025 年至 2033 年的複合年增長率為 10.11%。這一增長得益於人們對子宮頸癌認識的不斷提高、篩檢計畫的不斷推進以及全球醫療保健系統診斷技術的進步。

人類乳突病毒 (HPV) 檢測市場成長動力

提高意識和政府篩檢計畫

國際宣傳項目和國家篩檢計畫顯著增加了 HPV 檢測的需求。已開發經濟體和新興經濟體的政府都已推出指南，要求30歲及以上女性定期進行子宮頸癌篩檢。世界衛生組織（WHO）等組織倡導HPV檢測作為早期發現癌症的關鍵工具。人們對HPV相關癌症的認識不斷提高以及疫苗接種也推動了這項需求。這些措施將有助於更早診斷、更快介入，並減輕HPV相關疾病的整體負擔，從而推動市場向前發展。 2024年9月，美國、澳洲、印度和日本將​​在印度-太平洋地區大力展開對抗子宮頸癌的行動。這些行動是四方領導人峰會上宣布的一項重大舉措的一部分。

HPV檢測的技術突破

PCR、新一代定序和自採集試劑盒等診斷技術的創新，透過提高準確性、可及性和便利性，徹底改變了HPV檢測。自動化平台、多重檢測和液基細胞學技術可以縮短檢測週期並實現大規模篩檢。這些技術在資源匱乏的環境中尤其有價值，使其能夠在公共衛生系統中得到更廣泛的應用。診斷公司持續的研發投入有助於提高檢測的靈敏度和可用性，從而進一步推動市場成長。 2023年6月，世界衛生組織初步核准了第四種人類乳突病毒 (HPV) 檢測方法。 HPV 檢測對於子宮頸癌篩檢至關重要，因為大多數 HPV 感染會自然消退，但多種高風險 HPV 類型都可能導致子宮頸癌。

HPV 相關癌症盛行率上升

全球 HPV 相關癌症（尤其是子宮頸癌）發生率的上升是強大的市場驅動力。據世界衛生組織稱，子宮頸癌是全球第四大常見女性癌症，其中絕大多數是由高危險 HPV 類型引起的。癌症患者數量的增加增加了對早期檢測策略的需求，使 HPV 檢測成為預防醫學的核心。隨著醫療保健專業人員和患者尋求可靠的診斷方法，HPV 檢測也正成為女性醫療保健的重要組成部分。在美國，每年約有47,984例新發癌症病例發生在人類乳突病毒 (HPV) 常見的身體部位。

人類乳突病毒 (HPV) 檢測市場面臨的課題

低收入國家/地區的可近性受限

儘管 HPV 檢測在全球範圍內得到認可，但由於缺乏醫療保健基礎設施和資源，在中低收入國家/地區並不容易獲得。大多數地區缺乏檢測設施、訓練有素的專業人員和定期篩檢項目。文化禁忌和性歧視也阻礙了人們參與 HPV 檢測。這種差異導致人們無法獲得早期診斷，並增加了晚期子宮頸癌的風險。透過經濟高效的即時診斷和教育計劃克服這些障礙，對於公平的市場擴張至關重要。

先進HPV偵測技術成本高

先進的HPV檢測技術（包括基於PCR的平台和DNA定序）的價格可能超出醫療保健系統和某些患者的承受能力。由於已開發國家已將這些技術用於常規篩檢，因此價格差異限制了其在資源匱乏地區的應用。此外，維護成本、品質保證以及對專業人員的需求導致診所和實驗室的運作成本高昂。這項成本因素阻礙了大規模篩檢活動的發展，尤其是在發展中國家。

本報告提供全球人類乳突病毒(HPV)檢驗市場相關調查，成長推動因素與課題，各市場區隔的分析，主要企業的分析等資訊。

目錄

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 市場動態

• 成長促進因素
• 課題

第5章 人類乳突病毒(HPV)檢驗市場

• 過去的市場趨勢
• 市場預測

第6章 人類乳突病毒(HPV)檢驗的市場佔有率分析

• 各用途
• 各產品
• 各技術
• 各最終用途
• 各國

第7章 用途

• 子宮頸癌症診察
• 陰道癌症診察

第8章 產品

• 消耗品
• 器具
• 服務

第9章 技術

• 聚合酵素鏈鎖反應(PCR)
• 液狀化檢體細胞診斷
• 免疫診斷
• 雜交捕獲
• 其他

第10章 最終用途

• 醫院·診療所
• 研究所
• 其他

第11章 國家

• 北美
  • 美國
  • 加拿大
• 歐洲
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 比利時
  • 荷蘭
  • 土耳其
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 韓國
  • 泰國
  • 馬來西亞
  • 印尼
  • 澳洲
  • 紐西蘭
• 南美
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東·非洲
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第12章 波特的五力分析

第13章 SWOT分析

第14章 主要企業的分析

• Abbott Laboratories
• BioMerieux SA
• Bio-Rad Laboratories, Inc.
• Epigenomics AG
• Siemens Healthineers AG
• Hologic Inc
• Qiagen NV
• F. Hoffmann-La Roche Ltd

Human Papilloma Virus (HPV) Testing Market Trends & Summary

The Human papillomavirus (HPV) Testing Market was USD 1.52 billion in 2024 and is expected to reach USD 3.62 billion by 2033, with a CAGR of 10.11% from 2025 to 2033. The growth is due to increasing awareness of cervical cancer, increased screening programs, and technological advancements in diagnostic technologies in global healthcare systems.

The report Human Papilloma Virus (HPV) Testing Market & Forecast covers by Application (Cervical Cancer Screening, Vaginal Cancer Screening), Product (Consumables, Instruments, Services), Technology (Polymerase chain reaction (PCR), Liquid-based cytology, Immunodiagnostics, Hybrid Capture, Others), End Use (Hospitals & Clinics, Laboratories, Others), Countries and Company analysis 2025-2033.

Human Papilloma Virus (HPV) Testing Market Outlooks

Human Papilloma Virus (HPV) testing is a clinical diagnostic test conducted to identify the existence of HPV DNA or RNA in cells, mostly from the cervix. HPV is an epidemic sexually transmitted infection and some high-risk types are recognized to be causative for cervical cancer, as well as other anogenital and oropharyngeal cancers. HPV testing is generally done in regular cervical cancer screenings, typically at the same time or after a Pap test. It allows identifying women who are at risk prior to cell abnormality occurrence so that it may be prevented or treated early.

Internationally, the use of HPV testing is increasing with growing awareness regarding prevention of cervical cancer, government-sponsored screening programs, and WHO's initiative to eliminate cervical cancer as a public health issue. Developed countries have embraced HPV-based screening on a large scale, and developing nations are also adopting it, with the support of global health programs. Its high sensitivity and long-term risk prediction make it a method of choice in contemporary gynecological practice.

Growth Driver in the Human Papilloma Virus (HPV) Testing Market

Increasing Awareness and Government Screening Programs

International awareness programs and country-level screening programs have increased demand for HPV testing to a large extent. Governments in developed and emerging economies are adopting routine cervical cancer screening guidelines for women aged 30 and older. WHO organizations advocate for HPV testing as a key tool for early detection of cancer. Greater awareness of HPV-associated cancers and immunization also reinforces demand. These efforts account for early diagnosis, prompt intervention, and overall reduction in HPV-associated disease burden, thus driving the market forward. SEP 2024, The United States, Australia, India, and Japan are rolling out a key initiative to fight cervical cancer across the Indo-Pacific, a preventable disease which is a significant health crisis in the region. This initiative is part of larger announcements made during the Quad Leaders Summit.

Technological Breakthroughs in HPV Testing

Innovation in diagnostic methods-like PCR, next-generation sequencing, and self-sampling kits-has revolutionized HPV testing by enhancing accuracy, accessibility, and convenience. Automated platforms, multiplex assays, and liquid-based cytology enable quicker turnaround times and large-scale screening. These technologies are particularly precious in resource-poor settings and enable wider adoption in public health systems. Ongoing R&D spending by diagnostic firms serves to improve test sensitivity and affordability, fueling additional market growth. June 2023, The WHO has prequalified a fourth test for human papillomavirus (HPV). Although most HPV infections will clear on their own, a few of the higher-risk types can cause cervical cancer, so HPV testing is important for cervical cancer screening.

Rising Prevalence of HPV-Associated Cancers

Growing global incidence of HPV-related cancers, particularly cervical cancer, is a strong market driver. Cervical cancer is the fourth leading female cancer in the world according to the WHO, and the overwhelming majority of cases are caused by high-risk HPV types. Growing cases of cancer have driven the need for early detection strategies, putting HPV testing at the center of preventive medicine. As healthcare professionals and patients strive for surefire diagnostic measures, HPV testing is also becoming a necessity in women's health care. An estimated 47,984 new cases of cancer occur each year in the United States in areas of the body where human papillomavirus (HPV) commonly occurs.

Challenge in the Human Papilloma Virus (HPV) Testing Market

Limited Access in Low-Income Countries

In spite of worldwide awareness, HPV testing is not readily available in low- and middle-income countries because of a lack of healthcare infrastructure and resources. There are few laboratory facilities, skilled professionals, and regular screening programs in most areas. Cultural taboo and sexual stigma also discourage HPV testing participation. This inequality avoids early diagnosis and enhances the risk of cervical cancer at advanced stages. It is essential to overcome these barriers using cost-effective point-of-care diagnostics and education initiatives for equitable market expansion.

Exorbitant Cost of Sophisticated HPV Testing Technologies

The price of advanced HPV testing technologies, including PCR-based platforms and DNA sequencing, can be out of reach for healthcare systems and some patients. As developed nations implement these technologies into regular screening, the affordability gap restricts accessibility in resource-scarce settings. In addition, maintenance costs, quality assurance, and specialized staff requirements contribute to higher operating costs for clinics and laboratories. This cost factor hinders mass screening activities, particularly in developing countries.

Human Papilloma Virus Cervical Cancer Testing Market

Cervical cancer testing is the leading segment in the HPV testing market. Almost all cervical cancers are associated with persistent infection with high-risk HPV types, so early detection is essential. Governments and NGOs are encouraging HPV-based cervical cancer screening to supplement or replace conventional Pap smears. Incorporation of HPV DNA testing in primary screening algorithms enhances detection rates and long-term surveillance. This trend has raised the demand for dependable, sensitive, and scalable testing solutions, considerably boosting the cervical cancer testing market.

Consumables Human Papilloma Virus Testing Market

Consumables such as reagents, assay kits, swabs, and sample collection devices make up a crucial part of the HPV testing market. With reoccurring testing and increasing use of self-sampling kits, the need for superior consumables is increasing consistently. Diagnostic clinics and laboratories depend on regular supply and compatibility with multiple automated platforms. Additionally, innovation in multiplex testing and sample preservation has resulted in the creation of sophisticated consumables, providing improved stability and accuracy. This consumables segment provides recurring revenue, supporting market growth.

Immunodiagnostics Human Papilloma Virus Testing Market

Immunodiagnostics HPV tests identify particular viral proteins or host immune reactions through antibody-antigen interactions. These assays are simpler than molecular methods and are commonly employed in screening programs, especially in resource-constrained environments. They represent a cost-saving alternative for identifying high-risk HPV types and early cervical lesions. While less sensitive than PCR, continued advances in immunoassay design and the discovery of biomarkers are improving reliability. This section is important in making HPV testing available in various healthcare settings.

Polymerase Chain Reaction (PCR) Human Papilloma Virus Testing Market

PCR-based HPV tests are considered the gold standard for high-risk HPV detection based on their enhanced sensitivity and specificity. Multiple HPV genotypes can be identified with these tests in a single assay, which facilitates accurate risk stratification and monitoring. Increasing clinical use of real-time PCR and multiplex platforms has driven the market strongly. Automation and cost-saving measures are rendering PCR testing more viable in large-scale screening programs. With precision diagnostics becoming more prominent, PCR continues to be a mainstay in HPV testing.

Human Papilloma Virus Testing Laboratories Market

Test-based HPV laboratory testing leads the market with high-volume, high-precision, scalable offerings of centralized laboratories. The laboratories provide standardized test protocols to hospitals, public health programs, and private clinics. Diagnostic laboratories are embracing automation, high-capacity platforms, and LIMS integration as demand for cervical cancer screening increases. Reference laboratories and outsourcing services have led to strong, long-term growth for this market segment.

United States Human Papilloma Virus Testing Market

The U.S. market for HPV testing is developed and ongoing because of extensive awareness, national screening initiatives, and high usage of sophisticated diagnostics. Routine screening for HPV in women is advised by the CDC, and the services are usually covered by insurers. Technological advancements, robust regulatory backing, and dominance of major players make the U.S. a focal point for HPV diagnostics. Demand for home and self-collection kits is also increasing, thus fueling diversification in the market.

France Human Papilloma Virus Testing Market

In France, the HPV testing market is growing steadily with the integration of HPV screening into the national health system. Since 2020, HPV testing has been recommended as the primary screening method for women aged 30 and above, replacing the Pap smear. The French government subsidizes screening, raising participation and test volumes. With a solid public health infrastructure and improving awareness, the market is moving toward automated molecular testing platforms and large-scale laboratory operations.

India Human Papilloma Virus Testing Market

India's HPV testing market is in the growth stage, fueled by rising awareness and pilot screening across different states. Adoption is restricted to urban areas and private healthcare due to cost and infrastructure reasons. Government and NGOs are enforcing broader accessibility through low-cost testing solutions and mobile health vans. With a heavy load of cervical cancer, India has huge long-term potential, particularly as domestic manufacturers and public policy reduce costs.

Saudi Arabia Human Papilloma Virus Testing Market

The Saudi Arabian market for HPV testing is growing as the government continues to focus more on women's health and prevention of cancer. The Ministry of Health is initiating HPV vaccination and screening programs, particularly in private clinics and urban hospitals. Despite initial resistance from cultural sensitivity, awareness campaigns and education are slowly enhancing test acceptance. With a young, technologically savvy population and continued healthcare reform under Vision 2030, Saudi Arabia has the potential to become a dominant force in regional HPV diagnostics market.

Human Papilloma Virus Testing Market Segmentation

Application

• Cervical Cancer Screening
• Vaginal Cancer Screening

Product

• Consumables
• Instruments
• Services

Technology

• Polymerase chain reaction (PCR)
• Liquid-based cytology
• Immunodiagnostics
• Hybrid Capture
• Others

End Use

• Hospitals & Clinics
• Laboratories
• Others

Countries

North America

• United States
• Canada

Europe

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Turkey

Asia Pacific

• China
• Japan
• India
• South Korea
• Thailand
• Malaysia
• Indonesia
• Australia
• New Zealand

Latin America

• Brazil
• Mexico
• Argentina

Middle East & Africa

• Saudi Arabia
• UAE
• South Africa

All companies have been covered

• Overview
• Key Persons
• Recent Development & Strategies
• Financial Insights

Company Analysis

• Abbott Laboratories
• BioMerieux SA
• Bio-Rad Laboratories, Inc.
• Epigenomics AG
• Siemens Healthineers AG
• Hologic Inc
• Qiagen NV
• F. Hoffmann-La Roche Ltd

Table of Contents

1. Introduction

2. Research Methodology

• 2.1 Data Source
  • 2.1.1 Primary Sources
  • 2.1.2 Secondary Sources
• 2.2 Research Approach
  • 2.2.1 Top-Down Approach
  • 2.2.2 Bottom-Up Approach
• 2.3 Forecast Projection Methodology

3. Executive Summary

4. Market Dynamics

• 4.1 Growth Drivers
• 4.2 Challenges

5. Human Papilloma Virus Testing Market

• 5.1 Historical Market Trends
• 5.2 Market Forecast

6. Human Papilloma Virus Testing Market Share Analysis

• 6.1 By Application
• 6.2 By Product
• 6.3 By Technology
• 6.4 By End Use
• 6.5 By Countries

7. Application

• 7.1 Cervical Cancer Screening
• 7.2 Vaginal Cancer Screening

8. Product

• 8.1 Consumables
• 8.2 Instruments
• 8.3 Services

9. Technology

• 9.1 Polymerase chain reaction (PCR)
• 9.2 Liquid-based cytology
• 9.3 Immunodiagnostics
• 9.4 Hybrid Capture
• 9.5 Others

10. End Use

• 10.1 Hospitals & Clinics
• 10.2 Laboratories
• 10.3 Others

11. Countries

• 11.1 North America
  • 11.1.1 United States
  • 11.1.2 Canada
• 11.2 Europe
  • 11.2.1 France
  • 11.2.2 Germany
  • 11.2.3 Italy
  • 11.2.4 Spain
  • 11.2.5 United Kingdom
  • 11.2.6 Belgium
  • 11.2.7 Netherlands
  • 11.2.8 Turkey
• 11.3 Asia Pacific
  • 11.3.1 China
  • 11.3.2 Japan
  • 11.3.3 India
  • 11.3.4 South Korea
  • 11.3.5 Thailand
  • 11.3.6 Malaysia
  • 11.3.7 Indonesia
  • 11.3.8 Australia
  • 11.3.9 New Zealand
• 11.4 Latin America
  • 11.4.1 Brazil
  • 11.4.2 Mexico
  • 11.4.3 Argentina
• 11.5 Middle East & Africa
  • 11.5.1 Saudi Arabia
  • 11.5.2 UAE
  • 11.5.3 South Africa

12. Porter's Five Forces Analysis

• 12.1 Bargaining Power of Buyers
• 12.2 Bargaining Power of Suppliers
• 12.3 Degree of Rivalry
• 12.4 Threat of New Entrants
• 12.5 Threat of Substitutes

13. SWOT Analysis

• 13.1 Strength
• 13.2 Weakness
• 13.3 Opportunity
• 13.4 Threat

14. Key Players Analysis

• 14.1 Abbott Laboratories
  • 14.1.1 Overview
  • 14.1.2 Key Persons
  • 14.1.3 Recent Development & Strategies
  • 14.1.4 Revenue Analysis
• 14.2 BioMerieux SA
  • 14.2.1 Overview
  • 14.2.2 Key Persons
  • 14.2.3 Recent Development & Strategies
  • 14.2.4 Revenue Analysis
• 14.3 Bio-Rad Laboratories, Inc.
  • 14.3.1 Overview
  • 14.3.2 Key Persons
  • 14.3.3 Recent Development & Strategies
  • 14.3.4 Revenue Analysis
• 14.4 Epigenomics AG
  • 14.4.1 Overview
  • 14.4.2 Key Persons
  • 14.4.3 Recent Development & Strategies
  • 14.4.4 Revenue Analysis
• 14.5 Siemens Healthineers AG
  • 14.5.1 Overview
  • 14.5.2 Key Persons
  • 14.5.3 Recent Development & Strategies
  • 14.5.4 Revenue Analysis
• 14.6 Hologic Inc
  • 14.6.1 Overview
  • 14.6.2 Key Persons
  • 14.6.3 Recent Development & Strategies
  • 14.6.4 Revenue Analysis
• 14.7 Qiagen NV
  • 14.7.1 Overview
  • 14.7.2 Key Persons
  • 14.7.3 Recent Development & Strategies
  • 14.7.4 Revenue Analysis
• 14.8 F. Hoffmann-La Roche Ltd
  • 14.8.1 Overview
  • 14.8.2 Key Persons
  • 14.8.3 Recent Development & Strategies
  • 14.8.4 Revenue Analysis